Skip to main content
    R

    Rani Therapeutics Holdings Inc (RANI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.54
    +0.01 (+2.66%)

    Market Cap: $60.78M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Rani Therapeutics Holdings Inc (RANI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Rani Therapeutics Holdings reported revenue of $1.63M for the fiscal year ended Dec 31, 2025, up 58.9% from the year before. That year, net income was -$40.95M with a net margin of -2507.7%, operating cash flow was -$18.71M and free cash flow was -$18.80M. The quarter ended Sep 30, 2026 had revenue of $1.71M and net income of -$8.81M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue grew from $979.00K, a compound annual rate of 8.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.63M+58.9%100.0%-2346.0%-2507.7%
    Dec 2024$1.03MN/A100.0%-5186.2%-5504.3%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$462.00K-52.8%100.0%-3581.0%-3615.4%
    Dec 2019$979.00KN/A100.0%-2764.6%-2716.8%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$1.63M$1.03M$0$0$0$462.00K$979.00K
    Gross profit$1.63M$1.03M$0$0$0$462.00K$979.00K
    Research and development$20.20M$26.68M$39.62M$36.61M$26.48M$12.04M$24.58M
    Operating income-$38.31M-$53.31M-$66.10M-$63.45M-$54.32M-$16.54M-$27.07M
    Net income-$40.95M-$56.58M-$67.88M-$63.34M-$53.09M-$16.70M-$26.60M
    EBITDA-$37.48M-$53.30MN/AN/A-$54.19M-$16.02M-$26.01M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.71M$1.71M$1.71M$1.46M$0$0$172.00K$1.03M$0$0$0$2.75M
    Gross profit$1.71M$1.71M$1.71M$1.46M$0$0$172.00K$1.03M$0$0$0$2.52M
    Operating income-$9.22M-$8.83M-$8.34M-$8.54M-$7.26M-$10.51M-$12.01M-$14.96M-$11.80M-$12.52M-$14.03M-$13.43M
    Net income-$8.81M-$8.42M-$8.02M-$9.07M-$7.91M-$11.22M-$12.74M-$15.72M-$12.72M-$13.36M-$14.78M-$14.05M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.59M by $17.03M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$58.62M$36.63M$57.92M$108.03M$124.21M$79.42M$23.02M
    Current assets$53.32M$29.74M$50.85M$100.92M$119.59M$74.94M$16.94M
    Cash and equivalents$18.62M$3.76M$5.86M$27.01M$117.45M$73.06M$16.54M
    Total liabilities$17.11M$33.14M$32.47M$34.02M$2.64M$8.04M$119.66M
    Short-term debt$1.59M$15.00M$4.90M$0$0$1.36MN/A
    Long-term debtN/A$9.61M$24.48M$29.15M$0$2.41MN/A
    Shareholder equity$33.01M$1.99M$12.87M$36.85M$47.41M-$113.34M-$96.64M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$52.53M$60.84M$51.88M$58.62M$10.14M$16.90M$24.13M$36.63M$43.54M$43.73M$53.51M$57.92M
    Total liabilities$11.18M$12.86M$16.34M$17.11M$22.11M$26.05M$29.47M$33.14M$37.77M$38.18M$38.98M$32.47M
    Cash and equivalents$3.62M$4.87M$9.64M$18.62M$4.14M$10.22M$10.11M$3.76M$4.28M$4.51M$6.88M$5.86M
    Shareholder equity$33.97M$39.23M$28.41M$33.01M-$7.86M-$5.58M-$3.06M$1.99M$3.12M$2.83M$7.40M$12.87M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$18.71M-$35.50M-$51.24M-$46.52M-$32.24M-$14.96M-$26.27M
    Capital expenditures$88.00K$268.00K$1.23M$1.62M$506.00K$1.20M$1.58M
    Free cash flow-$18.80M-$35.76M-$52.47M-$48.13M-$32.75M-$16.16M-$27.85M
    Dividends paidN/AN/AN/A$29.63MN/AN/AN/A
    Investing cash flow-$7.03M$19.81M$29.86M-$72.44M-$506.00K-$1.20M-$1.53M
    Financing cash flow$40.30M$13.59M$233.00K$29.00M$77.15M$72.68M$852.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$7.76M-$9.03M-$6.50M$294.00K-$5.06M-$5.80M-$8.15M-$8.65M-$8.41M-$9.03M-$9.40M-$12.48M
    Capital expenditures$183.00K$32.00K$15.00K$0$0$37.00K$51.00K$31.00K$125.00K$94.00K$18.00K$167.00K
    Free cash flow-$7.94M-$9.06M-$6.51M$294.00K-$5.06M-$5.83M-$8.20M-$8.69M-$8.54M-$9.12M-$9.42M-$12.64M
    Last 12 quarters

    Frequently Asked Questions About RANI

    What is Rani Therapeutics Holdings' annual revenue?

    Rani Therapeutics Holdings reported revenue of $1.63M for the fiscal year ended Dec 31, 2025.

    How fast is Rani Therapeutics Holdings' revenue growing?

    Revenue was up 58.9% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Rani Therapeutics Holdings profitable?

    No. Rani Therapeutics Holdings reported net income of -$40.95M for the fiscal year ended Dec 31, 2025, with a net margin of -2507.7%.

    How much free cash flow does RANI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$18.71M minus capital expenditures of $88.00K produced free cash flow of -$18.80M.

    How much debt does Rani Therapeutics Holdings have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.59M and cash and equivalents of $18.62M.